JOT a Clinical stage company focusing on CNS Diseases JOT is a virtually based company with a strong, experienced core management team. JOT utilizes the strength of its partners and advisors from both industry and academia JOT’s long-term focus is developing a treatment for Alzheimer’s Disease (AD), while in parallel develop one or more treatments for rare diseases. JOT’s unique resveratrol formulation, JOTROLTM, is the first product in the world to allow delivery of safe, therapeutic doses of resveratrol. JOTROLTM, is enabling JOT to use 1 product for multiple diseases. Less risk, more opportunities and faster to market.
Jupiter Orphan Therapeutics is presenting as part of the NIH Innovation Zone.